Program
CHO cell
Also written as “Recombinant new coronavirus vaccine (CHO cell) group”, “Recombinant Zoster Vaccine (CHO Cell)” and “Recombinant two-component COVID-19 vaccine (CHO cell)”.
Its studies are mostly in COVID-19 · Herpes Zoster · Coronavirus Infections · Kidney Failure, Chronic, led by 7 companies.
Drug pageCHO cell: every studyMany companies study it; this page follows only the 29 they lead. All 35 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Zhifei Biological Products | 121 open or running | phase 4since Mar 28, 2022 | Jun 16, 2020 | none ahead |
| Jiangsu Rec-Biotechnologyits history only | 50 open or running | phase 3since May 30, 2022 | Mar 19, 2021 | none ahead |
| MAXVAX Biotechnology Limited Liabilityits history only | 54 open or running | phase 3since Jun 2, 2024 | Jun 2, 2024 | Dec 31, 2027phase 3 · NCT07293065 |
| 3SBioits history only | 20 open or running | phase 3since Jan 13, 2022 | May 10, 2019 | none ahead |
| Guangzhou Patronus Biotechits history only | 20 open or running | phase 3since Dec 23, 2022 | Dec 23, 2022 | none ahead |
| Sinopharmits history only | 20 open or running | phase 2since Apr 24, 2021 | Apr 24, 2021 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 2since Oct 19, 2026 | Oct 19, 2026 | Jul 31, 2027phase 2 · NCT07892989 |
Also a collaborator on its studies: Yantai Patronus Biotech and Iqvia Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chongqing Zhifei Biological Products only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2020First study: phase 1 study in Coronavirus InfectionsFirst studyNCT04445194 · 50 enrolled · China
- Jul 8, 2020Phase 2 study in Coronavirus InfectionsNCT04466085 · 900 enrolled · China
- Aug 16, 2020Phase 1 study in Coronavirus InfectionsNCT04550351 · 50 enrolled · China
- Nov 25, 2020Phase 3 study in Prevention of COVID-19NCT04646590 · 28,904 enrolled · China, Ecuador, Indonesia and more
- Jul 8, 2021Phase 1 study in Coronavirus InfectionsNCT04961359 · 75 enrolled · China
- Oct 11, 2021No phase study in COVID-19NCT05089045 · 360 enrolled · China
- Oct 12, 2021Phase 3 study in COVID-19NCT05091411 · 1,680 enrolled · China
- Nov 1, 20212 phase 3 studies in COVID-19NCT05107375, NCT05128643
- Nov 4, 2021Phase 2 study in COVID-19NCT05109598 · 400 enrolled · China
- Mar 28, 2022Phase 4 study in COVID-19NCT05890521 · 100,000 planned · China
- Oct 10, 2022No phase study in COVID-19NCT05574985 · 272 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 Chongqing Zhifei Biological Products leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05574985COVID-19 · China | – | Completed | Oct 9, 2022 | 272 |
| NCT05890521COVID-19 · China | 4 | Recruiting | Jun 16, 2022 | 100,000 |
| NCT05128643COVID-19 · China | 3 | UNKNOWN | Apr 12, 2022 | 300 |
| NCT05109598COVID-19 · China | 2 | Completed | Feb 14, 2022 | 400 |
| NCT05107375COVID-19 · China | 3 | Completed | Mar 4, 2022 | 299 |
| NCT05091411COVID-19 · China | 3 | UNKNOWN | Nov 2021 | 1,680 |
| NCT05089045COVID-19 · China | – | Completed | Sep 16, 2021 | 360 |
| NCT04961359Coronavirus Infections · China | 1 | Completed | Dec 12, 2021 | 75 |
| NCT04646590Prevention of COVID-19 · China, Ecuador, Indonesia and more | 3 | UNKNOWN | Nov 28, 2021 | 28,904 |
| NCT04550351Coronavirus Infections · China | 1 | UNKNOWN | Dec 18, 2020 | 50 |
| NCT04466085Coronavirus Infections · China | 2 | UNKNOWN | Oct 22, 2020 | 900 |
| NCT04445194Coronavirus Infections · China | 1 | UNKNOWN | Oct 22, 2020 | 50 |
How it is read
Names in the registry
- “Recombinant new coronavirus vaccine (CHO cell) group”, 5 entries
- “Recombinant Zoster Vaccine (CHO Cell)”, 3 entries
- “Recombinant two-component COVID-19 vaccine (CHO cell)”, 3 entries
- “Recombinant RSV Vaccine (CHO Cell)”, 2 entries
- “Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)”, 2 entries
Conditions, from the studies’ own filings
- COVID-19, 16 studies
- Herpes Zoster, 5 studies
- Coronavirus Infections, 4 studies
- Kidney Failure, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.